Safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose anti-interleukin-18 mAb GSK1070806 in healthy and obese subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 52, Issue 10, 2014, Pages 867-879

  Mistry, Prafull ^a   Reid, Juliet ^a   Pouliquen, Isabelle ^a   McHugh, Simon ^b   Abberley, Lee ^c   DeWall, Stephen ^c   Taylor, Adam ^a   Tong, Xin ^a   Cura, Marian Rocha Del ^a   McKie, Elizabeth ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

18 monoclonal antibody (mAb); Anti interleukin (Il); GSK1070806; Pharmacodynamics; Pharmacokinetics; Safety

Indexed keywords

GAMMA INTERFERON; GSK 1070806; IMMUNOGLOBULIN G1; INTERLEUKIN 18; INTERLEUKIN 18 ANTIBODY; MONOCLONAL ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; GSK1070806;

ADULT; AGED; ALLERGY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTACT DERMATITIS; CONTROLLED STUDY; COUGHING; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERYTHEMA; EX VIVO STUDY; FEMALE; FLATULENCE; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; LETHARGY; LYMPHADENOPATHY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NORMAL HUMAN; NOSE OBSTRUCTION; OBESITY; OROPHARYNX PAIN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RHINORRHEA; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; VOLUME OF DISTRIBUTION; ADOLESCENT; IMMUNOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INTERLEUKIN-18; MALE; MIDDLE AGED; OBESITY; SINGLE-BLIND METHOD;

EID: 84926619977     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202087     Document Type: Article

References (43)

1. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, Akita K, Namba M, Tanabe F, Konishi K, Fukuda S, Kurimoto M. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995; 378: 88-91.
2. Dinarello CA, Novick D, Puren AJ, Fantuzzi G, Shapiro L, Mühl H, Yoon DY, Reznikov LL, Kim SH, Rubinstein M. Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leukoc Biol. 1998; 63: 658-664.
3. Micallef MJ, Ohtsuki T, Kohno K, Tanabe F, Ushio S, Namba M, Tanimoto T, Torigoe K, Fujii M, Ikeda M, Fukuda S, Kurimoto M. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol. 1996; 26: 1647-1651.
4. Puren AJ, Fantuzzi G, Gu Y, Su MS, Dinarello CA. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest. 1998; 101: 711-721.
5. Amin MA, Mansfield PJ, Pakozdi A, Campbell PL, Ahmed S, Martinez RJ, Koch AE. Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum. 2007; 56: 1787-1797.
6. Tomura M, Zhou XY, Maruo S, Ahn HJ, Hamaoka T, Okamura H, Nakanishi K, Tanimoto T, Kurimoto M, Fujiwara H. A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3-cells. J Immunol. 1998; 160: 4738-4746.
7. Tominaga K, Yoshimoto T, Torigoe K, Kurimoto M, Matsui K, Hada T, Okamura H, Nakanishi K. IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells. Int Immunol. 2000; 12: 151-160.
8. Khan F, Peltekian KM, Peterson TC. Effect of interferon-alpha, ribavirin, pentoxifylline, and interleukin-18 antibody on hepatitis C sera-stimulated hepatic stellate cell proliferation. J Interferon Cytokine Res. 2008; 28: 643-651.
9. Jung MK, Song HK, Kim KE, Hur DY, Kim T, Bang S, Park H, Cho DH. IL-18 enhances the migration ability of murine melanoma cells through the generation of ROI and the MAPK pathway. Immunol Lett. 2006; 107: 125-130.
10. Park S, Cheon S, Cho D. The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol. 2007; 4: 329-335.
11. Boraschi D, Dinarello CA. IL-18 in autoimmunity: review, [review]. Eur Cytokine Netw. 2006; 17: 224-252.
12. Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, Kennedy K, Carter R, Wei XQ, Xu D, Field M, Foulis A, Liew FY, McInnes IB. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest. 1999; 104: 1393-1401.
13. Hu HZ, Li GL, Lim YK, Chan SH, Yap EH. Kinetics of interferon-gamma secretion and its regulatory factors in the early phase of acute graft-versus-host disease. Immunology. 1999; 98: 379-385.
14. Maerten P, Shen C, Colpaert S, Liu Z, Bullens DA, van Assche G, Penninckx F, Geboes K, Vanham G, Rutgeerts P, Ceuppens JL. Involvement of interleukin 18 in Crohn's disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models. Clin Exp Immunol. 2004; 135: 310-317.
15. Wild JS, Sigounas A, Sur N, Siddiqui MS, Alam R, Kurimoto M, Sur S. IFN-gamma-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma. J Immunol. 2000; 164: 2701-2710.
16. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y, Chvatchko Y, Tedgui A. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res. 2001; 89: E41-E45.
17. Yndestad A, Holm AM, Müller F, Simonsen S, Frøland SS, Gullestad L, Aukrust P. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res. 2003; 60: 141-146.
18. Sutinen EM, Pirttilä T, Anderson G, Salminen A, Ojala JO. Pro-inflammatory interleukin-18 increases Alzheimer's disease-associated amyloid-β production in human neuron-like cells. J Neuroinflammation. 2012; 9: 199.
19. Wildbaum G, Youssef S, Grabie N, Karin N. Neutralizing antibodies to IFN-gamma-inducing factor prevent experimental autoimmune encephalomyelitis. J Immunol. 1998; 161: 6368-6374.
20. Skurk T, Kolb H, Müller-Scholze S, Röhrig K, Hauner H, Herder C. The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. Eur J Endocrinol. 2005; 152: 863-868.
21. Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol. 2005; 25: 1268-1273.
22. Trøseid M, Seljeflot I, Arnesen H. The role of interleukin-18 in the metabolic syndrome. Cardiovasc Diabetol. 2010; 9: 11.
23. Oikawa Y, Shimada A, Kasuga A, Morimoto J, Osaki T, Tahara H, Miyazaki T, Tashiro F, Yamato E, Miyazaki J, Saruta T. Systemic administration of IL-18 promotes diabetes development in young nonobese diabetic mice. J Immunol. 2003; 171: 5865-5875.
24. Thorand B, Kolb H, Baumert J, Koenig W, Chambless L, Meisinger C, Illig T, Martin S, Herder C. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002. Diabetes. 2005; 54: 2932-2938.
25. Fujita T, Ogihara N, Kamura Y, Satomura A, Fuke Y, Shimizu C, Wada Y, Matsumoto K. Interleukin-18 contributes more closely to the progression of diabetic nephropathy than other diabetic complications. Acta Diabetol. 2012; 49: 111-117.
26. Hellemons ME, Kerschbaum J, Bakker SJ, Neuwirt H, Mayer B, Mayer G, de Zeeuw D, Lambers Heerspink HJ, Rudnicki M. Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review. Diabet Med. 2012; 29: 567-577.
27. Fischer CP, Perstrup LB, Berntsen A, Eskildsen P, Pedersen BK. Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clin Immunol. 2005; 117: 152-160.
28. Kim HJ, Kang ES, Kim DJ, Kim SH, Ahn CW, Cha BS, Nam M, Chung CH, Lee KW, Nam CM, Lee HC. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2007; 66: 282-289.
29. Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, Okamura H, Koga M, Fukuchi M, Hada T. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy Metabolism. 2003; 52: 605-608.
30. Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, Shah VP, Skelly JP, Swann PG, Weiner R. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res. 2007; 24: 1962-1973.
31. Ushio S, Namba M, Okura T, Hattori K, Nukada Y, Akita K, Tanabe F, Konishi K, Micallef M, Fujii M, Torigoe K, Tanimoto T, Fukuda S, Ikeda M, Okamura H, Kurimoto M. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol. 1996; 156: 4274-4279.
32. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010; 49: 633-659.
33. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010; 49: 493-507.
34. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006; 11: 81-88.
35. Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, Davis HM, Zhou H. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol. 2011; 72: 270-281.
36. Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet. 2011; 50: 215-227.
37. Hodsman P, Ashman C, Cahn A, De Boever E, Locantore N, Serone A, Pouliquen I. A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics. Br J Clin Pharmacol. 2013; 75: 118-128.
38. Chakraborty A, Tannenbaum S, Rordorf C, Lowe PJ, Floch D, Gram H, Roy S. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet. 2012; 51: e1-e18.
39. Tak PP, Bacchi M, Bertolino M. Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur J Drug Metab Pharmacokinet. 2006; 31: 109-116.
40. Struemper H, Koch KM, Bauman J, Robertson MJ, Toso JF. Physiologically-based model of recombinant human IL-18 pharmacokinetics. Poster presentation at American Conference of Pharmacometrics (ACoP), San Diego, CA, April 3-6, 2011. Available at: http://www.go-acop.org/sites/default/files/webform/posters/rhIL-18%20PK%20-%20ACOP%202011%20Poster%20-%20Herbert%20Struemper.pdf.
41. Murdolo G, Herder C, Wang Z, Rose B, Schmelz M, Jansson PA. In situ profiling of adipokines in subcutaneous microdialysates from lean and obese individuals. Am J Physiol Endocrinol Metab. 2008; 295: E1095-E1105.
42. Kohno K, Kataoka J, Ohtsuki T, Suemoto Y, Okamoto I, Usui M, Ikeda M, Kurimoto M. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol. 1997; 158: 1541-1550.
43. Ahn HJ, Maruo S, Tomura M, Mu J, Hamaoka T, Nakanishi K, Clark S, Kurimoto M, Okamura H, Fujiwara H. A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma. J Immunol. 1997; 159: 2125-2131.